Alfredo Addeo, MD Oncology Department, Geneva University Hospital, Geneva, Switzerland
Paolo A. Ascierto, MD Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Instituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy
B
Joaquim Bellmunt, MD, PhD Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Anders Bjartell, MD, PhD Department of Urology, Skåne University Hospital, Malmö, Sweden
Hossein Borghaei, MD Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
C
Fatima Cardoso, MD Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
Simon Chowdhury, PhD Consultant Medical Oncologist, London, UK
Eva M. Ciruelos, MD Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
Javier Cortes, MD Breast Cancer Research Program
Vall d’Hebron Institute of Oncology, Barcelona, Spain
Carmen Criscitiello, MD Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy
Giuseppe Curigliano, MD Division of Early Drug Development, European Institute of Oncology, Milan, Italy
D
Rebecca Dent, MD Division of Medical Oncology, National Cancer Center Singapore, Singapore
Véronique Diéras, MD Department of Medical Oncology, Centre Eugène Marquis, Rennes, France
Reinhard Dummer, MD Department of Dermatology, University of Zurich, Switzerland
Ignacio Duran, MD Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
E
Eleni Efstathiou, MD, PhD University of Texas MD Anderson Cancer Center, Houston, TX, USA
Hermann Einsele, MD Medizinische Klinik und Poliklinik II, ZIM, Universitätsklinikum Würzburg, Würzburg, Germany
Tarik Esen, MD School of Medicine, Koç University, Istanbul, Turkey
Toby Eyre, MD Oxford University Hospitals NHS Trust, Oxford, UK
F
Peter A. Fasching, MD Department of Gynecology and Obstetrics Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
Simone Ferrero, MD Department of Molecular Biotechnology and Health Sciences, Turin, Italy
G
Karen Gelmon, MD Department of Medical Oncology, BC Cancer Agency Vancouver, Vancouver, British Columbia, Canada
Alessandra Gennari, MD Department of Translational Medicine, University of Piemonte Orientale;
Division of Oncology, Maggiore della Carita Hospital, Novara, Italy
Nicolas Girard, MD Institut du Thorax Curie Montsouris, Institut Curie, Paris, France
Peter Goebell, MD Department of Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Frank Griesinger, MD Department of Hemtology and Oncology, Pius Hospital Oldenburg, Germany
Marc-Oliver Grimm, MD Department of Urology, University Hospital Jena, Germany
Petros Grivas, MD, PhD Division of Medical Oncology
University of Washington School of Medicine, Seattle, Washington, USA
Christian Grohé, MD Internal medicine, cardiology and pulmonology, Evangelical Lung Clinic, Johannesstift Diakonie, Berlin, Germany
Viktor Grünwald, MD Center for Uro-oncology, University Hospital Essen
Germany
Valentina Guarneri, MD, PhD University of Padua, Division of Oncology 2 at the Istituto Oncologico Veneto and University of Padova, Italy
H
Hans Hammers, MD, PhD Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medcial Center, Dallas, Texas, USA
Nadia Harbeck, MD Breast Center, Department of Obstetrics and Gynecology and CCCLMU, University of Munich, Germany
Axel Hauschild, MD Department of Dermatology, Venerology and Allergology, University Hospital Schleswig-Holstein (UKSH), Kiel, Germany
Matthew D. Hellmann, MD Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lizza Hendriks, MD Dept. of Pulmonary Diseases, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands
I
Philipp Ivanyi, MD Medizinische Hochschule Hannover, Germany
J
Wolfgang Janni, MD Universitätsklinikum Ulm, Ulm, Germany
Mats Jerkeman, MD Department of Hematology, Lund University Hospital, Lund, Sweden
Stephen R D Johnston, MD The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK
K
Laura-Maria Krabbe, MD Department of Urology, University of Münster, Münster, Germany
L
Marco Ladetto, MD Hematology Division, Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
C. Ola Landgren, MD Sylvester Comprehensive Cancer Center, Division of Hematology, University of Miami Health System, Miami, FL, US
Brea Lipe, MD University of Rochester Medical Center, Rochester, NY, USA
Stephen Liu, MD Thoracic Mecial Oncology and Developmental Therapeutics, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington D.C., USA
Georgina Long, MD Melanoma Institute Australia, The University of Sydney, Sydney, Australia;
Royal North Shore Hospital, St Leonards, NSW, Australia
Yohann Loriot, MD, PhD Department of Medical Oncology, Gustave Roussy, Villejuif, France
Ana Marín Niebla, MD Department of Hematology, Lymphoma Unit, University Hospital Vall d'Hebron, Barcelona, Spain
Axel S. Merseburger, MD Department of Urology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
Maximilian Merz, MD Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie, Universitätsklinikum Leipzig, Leipzig, Germany
Gil Morgan, MD Skåne University Hospital, Lund, Sweden
Alicia Morgans, MD Genitourinary Medical Oncologist
Dana-Farber Cancer Institute, Boston, USA
Denis Moro-Sibilot, MD Unité d’Oncologie Thoracique, Service Hospitalier Universitaire Pneumologie Physiologie Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, Grenoble, France
Volkmar Müller, MD Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Declan Murphy, MD Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne,
Australia
N
Paul Nathan, MD Department of Medical Oncology, Mount Vernon Cancer Centre, London, UK
Andrea Necchi, MD Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
P
Sumanta K. Pal, MD Genitourinary cancers, including kidney, bladder, and prostate cancer
City of Hope National Medical Center, Duarte, CA, USA
Shani Paluch-Shimon, MD Sharett Institute of Oncology Department, Hadassah University Hospital & Faculty of Medicine Hebrew University, Jerusalem, Israel
Barbara Pistilli, MD Breast Cancer Group, Gustave Roussy, Villejuif, France
Michael Postow, MD Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY, USA
Tom Powles, MD Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
R
Martin Reck, MD Lung Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany
Brian Rini, MD Vanderbilt-Ingram Cancer Center
Nashville, TN, USA
Sacha Rothschild, MD Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Basel, Basel, Switzerland
Hope Rugo, MD Department of Medicine (Hematology/Oncology), Breast Oncology and Clinical Trials Education, University of California San Francisco, CA, USA
S
Dirk Schadendorf, MD Department of Dermatology, University Hospital Essen, Germany
Fredrik Schjesvold, MD Oslo Myeloma Center at Oslo University Hospital, Oslo, Norway
Andreas Schneeweiss, MD Section gynecological oncology at the National Center for Tumor Diseases (Centrum für Tumorerkrankungen) (NCT) Heidelberg, Germany
Elzbieta Senkus-Konefka, MD Department of Oncology & Radiotherapy, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Riyaz Shah, MD Maidstone and Tunbridge Wells NHS Trust, Kent, UK
Neal Shore, MD Carolina Urologic Research Center and Atlantic Urology Clinics, LLC, Myrtle Beach, South Carolina, USA
Pieter Sonneveld, MD Erasmus MC Cancer Institute, Rotterdam, Netherlands
T
Daniel Shao-Weng Tan, MD Division of Medical Oncology at National Cancer Centre Singapore; Duke-NUS Medical School, Singapore
Catherine Thieblemont, MD Hemato-Oncology Department at Hôpital Saint-Louis, Paris, France
Michael Thomas, MD Thorax Clinic Heidelberg, Heidelberg University Hospital, Heidelberg, Germany
Sara Tolaney, MD Dana-Farber Cancer Institute, Harvard Medcial Scool, Boston, MA, USA
U
Michael Untch, MD Department of Gynaecology and Obstetrics, Breast Cancer and Gynecologic Oncology Center, HELIOS Klinikum Berlin Buch, Germany
W
Katja Weisel, MD Medizinische Klinik und Poliklinik, Zentrum für Onkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen!
Zu den Fragebögen
Nicht erneut anzeigen
CME Fortbildung – Zertifiziert durch die bayrische Landesärztekammer
Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Die Fortbildungseinheiten verteilen sich auf folgende Fortbildungsmodule:
Mammakarzinom / Gynäkologische Onkologie (Adjuvantes und metastasiertes Mammakarzinom, Gynäkologische Tumoren) maximal 4 CME Punkte
Urogenitale Tumoren (Nierenzellkarzinom, Prostatakarzinom, Urothelkarzinom) maximal 4 CME Punkte
Gastrointestinale Tumoren (Neuroendokrine Tumoren, Kolorektales-, Pankreas-, Gallengangs- und Hepatozelluläres Karzinom, sowie upper GI Tumoren) maximal 4 CME Punkte
CME Fortbildung – Zertifiziert durch die bayrische Landesärztekammer
Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Die Fortbildungseinheiten verteilen sich auf folgende Fortbildungsmodule:
Mammakarzinom / Gynäkologische Onkologie (Adjuvantes und metastasiertes Mammakarzinom, Gynäkologische Tumoren) maximal 4 CME Punkte
Urogenitale Tumoren (Nierenzellkarzinom, Prostatakarzinom, Urothelkarzinom) maximal 4 CME Punkte
Gastrointestinale Tumoren (Neuroendokrine Tumoren, Kolorektales-, Pankreas-, Gallengangs- und Hepatozelluläres Karzinom, sowie upper GI Tumoren) maximal 4 CME Punkte